Sydney Morning Herald
AsiaPac · 1 hrs ago
✦ 65◉ Centre
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
65Quality
0Ratings
0Comments
AI Analysis
Quality 65/100
Partisan intensity 45/100
ObjectivePartisan
◉ Centre ✓ Fair headline
NeuroScientific Biopharmaceuticals reports that its StemSmart stem cell therapy achieved an 80% clinical response rate in a small trial of five Crohn's disease patients, with all showing improvement.
NeuroScientific hails 80% clinical response in Crohn’s stem cell program
NeuroScientific Biopharmaceuticals has reported an 80% response rate from five Crohn’s disease patients treated with its StemSmart cell therapy, with all patients showing improvement.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!